Summary
None of the listed claims are assessable against the provided FDA label excerpts because they concern patient-assistance/eligibility/renewal, which are not present in the supplied prescribing information. Therefore support/contradiction cannot be established from the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Vascepa patient assistance programs typically allow annual renewal for eligible patients.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts (sections 1, 2, 4, 5, 6, 7, 8, 12, 14).
The Vascepa Savings Card offers co-pay reduction of up to $15 per fill with a maximum of $7,200 per year.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
The Vascepa Savings Card renews yearly if income and insurance criteria are met.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Patients must reapply or confirm eligibility online or by phone at the start of each calendar year for Savings Card renewal.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
The full Vascepa Patient Assistance Program (PAP) provides free medications for 12 months.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
The Vascepa PAP supports annual re-enrollment upon re-verification of finances and prescription needs.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa Savings Card eligibility requires commercial insurance and not government plans such as Medicare.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa PAP eligibility requires U.S. residency.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa PAP eligibility is based on household income up to 400-500% of the federal poverty level.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Renewal for the Vascepa Savings Card requires updating income documentation such as tax returns or pay stubs.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Renewal requires an active prescription from a doctor.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa program supplies are limited to 90-day fills and patients cannot stockpile.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Switching to Medicare ends eligibility for these programs.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Income exceeding program limits disqualifies renewal.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa program disqualification includes examples such as income limits of >$58,320 for a single person and >$124,800 for a family of four in 2024.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Job loss may allow reapplication mid-year as an edge case.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
There are no retroactive fills after a lapse.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Lapses in assistance result in full out-of-pocket costs estimated at $300-$500 per month.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Vascepa list price is approximately $320 for 120 capsules (about a one-month supply).
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Generics for Vascepa are not available yet due to patents expiring between 2035 and 2039.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Doctors must re-certify need annually for these programs.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Missing documentation can cause 20-30% denials for renewal.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Reapplying early (60 days before expiration) can help avoid renewal pitfalls.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
During shortages (e.g., in 2023), programs prioritize renewals but cap quantities.
Not supported or mentioned in the provided VASCEPA prescribing information excerpts.
Contradictions
Important Omissions
Any of the above patient-assistance/savings-card eligibility, renewal, documentation, copay caps, fill limits, shortage-handling, pricing, or patent/generic-availability statements are not addressed anywhere in the provided VASCEPA prescribing information excerpts, so the label-based accuracy check cannot verify them.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supplied prescribing information excerpts do not cover patient-assistance program details; therefore label-based risk assessment of these specific claims cannot be performed from the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims focus on patient assistance program and savings card operational details that are absent from the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Remove or qualify assistance-program operational claims, or support them with the specific official program terms (not the VASCEPA prescribing information). Ensure only label-supported product claims (indications, dosing, contraindications, warnings/precautions, adverse reactions, and label drug interactions) are evaluated and reported from the provided excerpts.